Skip to main content
. Author manuscript; available in PMC: 2013 Oct 24.
Published in final edited form as: Lab Invest. 2011 Feb 7;91(5):691–703. doi: 10.1038/labinvest.2011.5

Figure 4.

Figure 4

(a) Immunoblots showing Notch1 activation by 30-min treatment with pitavastatin (0–1.0 μmol/l), atorvastatin (10 nmol/l) and rosuvastatin (10 nmol/l). Experiments were performed three times with similar results. (b) Immunoblots showing the lack of effect of 30-min treatment with various concentrations of pitavastatin (0–10 μmol/l) on the expression of active Akt and Notch1 in HASMCs. (c) Effect of mevalonate (Mev) (200 μmol/l), PI3K inhibitor LY294002 (Ly) (10 μmol/l) and DAPT (20 μmol/l) in the absence or presence of pitavastatin (10 or 100 nmol/l, 30 min), atorvastatin (10 nmol/l, 30 min) and rosuvastatin (10 nmol/l, 30 min) on γ-secretase activity in human umbilical vein endothelial cells. *P<0.01 compared with control, **P<0.001 compared with control and #P<0.001 compared with pitavastatin 100 nmol/l alone. n = 3 for each group.